SUBJECT INDEX TO VOLUMES 3–4, 1979–1980

ACRYLICS

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.

The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.

Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.

ADVERTISING

"Big, bad Ayerst," in Washington report. James Dickinson. March 1980, p. 17.

"When ads mustn't tell the truth," in Washington report. James Dickinson. Feb. 1979, p. 21.

AEROSOLS

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

ANAEROBES (see also MICROBIOLOGY)

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

ANTACIDS

"Antacid market research by Richardson-Merrell," in London letter. Peter Bathe. Jan. 1980, p. 26.

ANTIBIOTICS

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.

"Can FDA be fair about Isolone?" in Washington report. James Dickinson. Feb. 1980, p. 22.

Dawn of the antibiotic era. John Parascandola. Nov. 1980, p. 60.

"Dr. Sidney Wolfe, 'a useful gadfly,' "in Washington report. James Dickinson. Jan. 1980, p. 21.

Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.

ASSAY AND BIOASSAY METHODS

Advances in HPLC: systems and uses. Dale R. Baker and John A. Michnowicz. May 1980, p. 56.

Automation in HPLC analysis. Hamed M. Abdou. May 1980, p. 70.

Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.

The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.

AUDITS

Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.

AUTOMATION

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.

Applications of microprocessor-based balances. Bernd Ludewig. May 1980, p. 40.

Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.

Automation in HPLC analysis. Hamed M. Abdou. May 1980, p. 70.

The automation of dissolution testing. John C. Wahlich. Sept. 1980, p. 92.

Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.

A computerized drug-stability system. Harold A. Stone and James G. Slater. April 1980, p. 52.

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.

Computerized weight-variation testing for uncoated tablets and capsules. Anthony N. Paruta, Thomas L. Breon, and Douglas S. Greene. March 1980, p. 84.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

An integrated computer network in pharmaceutical technology. Julian Horwich, Joan Fortune, Harvey J. Hoyt, and Ronald A. Schwartz. Jan. 1980, p. 54.

Office automation tools for the pharmaceutical laboratory. Caroline Watteeuw. June 1980, p. 42.

Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

BACTERIOLOGY (see also MICROBIOLOGY)

"The biotechnical revolution," in European report. Peter Bathe. May 1980, p. 26.

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

BALANCES

Applications of microprocessor-based balances. Bernd Ludewig. May 1980, p. 40.

This index was compiled by Robert Lee Hadden, MLS, of Tarboro, NC.

SUBJECT INDEX TO VOLUMES 3–4, 1979–1980

ACRYLICS

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.

The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.

Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.

ADVERTISING

"Big, bad Ayerst," in Washington report. James Dickinson. March 1980, p. 17.

"When ads mustn't tell the truth," in Washington report. James Dickinson. Feb. 1979, p. 21.

AEROSOLS

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

ANAEROBES (see also MICROBIOLOGY)

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

ANTACIDS

"Antacid market research by Richardson-Merrell," in London letter. Peter Bathe. Jan. 1980, p. 26.

ANTIBIOTICS

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.

"Can FDA be fair about Isolone?" in Washington report. James Dickinson. Feb. 1980, p. 22.

Dawn of the antibiotic era. John Parascandola. Nov. 1980, p. 60.

"Dr. Sidney Wolfe, 'a useful gadfly,' "in Washington report. James Dickinson. Jan. 1980, p. 21.

Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.

ASSAY AND BIOASSAY METHODS

Advances in HPLC: systems and uses. Dale R. Baker and John A. Michnowicz. May 1980, p. 56.

Automation in HPLC analysis. Hamed M. Abdou. May 1980, p. 70.

Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.

The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.

AUDITS

Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.

AUTOMATION

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.

Applications of microprocessor-based balances. Bernd Ludewig. May 1980, p. 40.

Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.

Automation in HPLC analysis. Hamed M. Abdou. May 1980, p. 70.

The automation of dissolution testing. John C. Wahlich. Sept. 1980, p. 92.

Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.

A computerized drug-stability system. Harold A. Stone and James G. Slater. April 1980, p. 52.

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.

Computerized weight-variation testing for uncoated tablets and capsules. Anthony N. Paruta, Thomas L. Breon, and Douglas S. Greene. March 1980, p. 84.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

An integrated computer network in pharmaceutical technology. Julian Horwich, Joan Fortune, Harvey J. Hoyt, and Ronald A. Schwartz. Jan. 1980, p. 54.

Office automation tools for the pharmaceutical laboratory. Caroline Watteeuw. June 1980, p. 42.

Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

BACTERIOLOGY (see also MICROBIOLOGY)

"The biotechnical revolution," in European report. Peter Bathe. May 1980, p. 26.

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

BALANCES

Applications of microprocessor-based balances. Bernd Ludewig. May 1980, p. 40.

This index was compiled by Robert Lee Hadden, MLS, of Tarboro, NC.

BENDECTIN

"Bendectin controversy," in European report. Peter Bathe. July 1980, p. 17.

"Bendectin/Debendox controversy," in European report. Peter Bathe. April 1980, p. 33.

BENZBROMARONE

The influence of media and volume on the dissolution rate of benzbromarone. Helga Möller. Sept. 1980, p. 116.

BENZODIAZEPINES

"Benzodiazepine treatment," in European report. Peter Bathe. July 1980, p. 17.

In behalf of balance and optimism. Irwin Lerner. April 1980, p. 12.

"Valium pricing battle," in European report. Peter Bathe. April 1980, p. 29.

BIOAVAILABILITY AND BIOEQUIVALENCE

The battle is over, but . . . . William F. Haddad. May 1979, p. 10.

Bioavailability of theophylline in soft-gelatin capsules. William R. Ebert. Oct. 1979, p. 60.

"Can you beat a MAC?" in Washington report. James Dickinson. Aug. 1979, p. 13.

"DESI's biggest compliance project," in Washington report. James Dickinson. Sept. 1979, p. 30.

Drug-product substitution and therapeutic equivalence. J. Richard Crout. June 1979, p. 56.

"Equivalence v. interchangeability," in Washington report. James Dickinson. Feb. 1979, p. 17.

"FDA versus Premo," in Washington report. James Dickinson. June 1980, p. 14.

"FDA versus Premo — part II," in Washington report. James Dickinson. Aug. 1980, p. 12.

London letter. Peter Bathe. Sept. 1979, p. 33.

A new era of tablet disintegrants. Ralph Shangraw, Ampol Mitrevej, and Manoj Shah. Oct. 1980, p. 48.

Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

"Tablets of stone," in Washington report. James Dickinson. Jan. 1979, p. 20.

Therapeutic equivalence in a restructured drug market. James Dickinson. April 1979, p. 72.

"USP's bottom line," in Washington report. James Dickinson. July 1980, p. 12.

BOOK REVIEWS

Anisfeld, Michael H., and Anisfeld, Evelyn R., eds., *International Drug G.M.P.'s*; reviewed by R. Murty, Sept. 1980, p. 177.

Banker, Gilbert S., and Rhodes, Christopher T., eds., *Modern Pharmaceutics*; reviewed by G. Zografi, Sept. 1980, p. 170.

Blanchard, J., Sawchuck, R.J., and Brodie, B.B., eds., *Principles and Perspectives in Drug Bioavailability*; reviewed by J. Swarbrick, June 1979, p. 48.

Connors, Kenneth A., Amidon, Gordon L., and Kennon, Lloyd, *Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists*; reviewed by J. Warren, July 1979, p. 74.

Cooper, Murray S., ed., *Quality Control in the Pharmaceutical Industry*, Vol. 3; reviewed by R. Murty, June 1980, p. 110.

Day, Robert A., *How to Write and Publish a Scientific Paper*; reviewed by R. Giovacchini, Sept. 1979, p. 118.

De Vita, Vincent T. Jr., and Busch, Harris, eds., *Methods in Cancer Research, Volume XVI: Cancer Drug Development Part A*; reviewed by J. Cohen, Sept. 1980, p. 167.

Gladsby, John S., *Encyclopedia of Antibiotics*, 2nd ed.; reviewed by J. Robbers, Feb. 1980, p. 79.

Goldberg, Morton E., ed., *Pharmacological and Biochemical Properties of Drug Substances*, Vol. 2; reviewed by J. Borowitz, April 1980, p. 70.

Goldenberg, Robert L., ed., *Advances in Cosmetic Technology*, Vol. 1; reviewed by P. Belcastro, June 1979, p. 50.

Griffiths, Mary C., ed., *USAN and the USP Dictionary of Drug Names*, 1981 ed., reviewed by P. Belcastro, Sept. 1979, p. 118.

Griffiths, Mary C., ed., *USAN and the USP Dictionary of Drug Names*, 1981 ed.; reviewed by P. Belcastro, Nov. 1980, p. 122.

Gutcho, M.H., *Microcapsules and Other Capsules — Advances Since 1975*; reviewed by P. Madan, March 1980, p. 142.

The Insight Team of *The Sunday Times* of London, *Suffer the Children: The Story of Thalidomide*; reviewed by M. Groves, May 1979, p. 84.

Lindsay, Cotton M., ed., *The Pharmaceutical Industry*; reviewed by E. Brady, Feb. 1980, p. 79.

McCrone, W.C., Kelly, J.G., and Palenik, S.J., *The Particle Atlas: Light Microscopy Atlas and Techniques*, Vol. V, 2nd ed.; reviewed by P. Belcastro, April 1980, p. 70.

McCrone, W.C., Brown, J.A., and Stewart, I.M., *The Particle Atlas: Electron Optical Atlas and Techniques*, Vol. VI, 2nd ed.; reviewed by P. Belcastro, June 1980, p. 108.

Nakamoto, Kazuo, *Infrared and Raman Spectra of Inorganic and Coordination Compounds*, 3rd ed.; reviewed by G. Schwartzman, Nov. 1979, p. 158.

Olson, E.C., and Christoffersen, R.E., ed., *Computer-Assisted Drug Design*; reviewed by D. Nichols, May 1980, p. 105.

Pharmaceutical Society of Great Britain, *The Pharmaceutical Codex*, 11th ed.; reviewed by P. Belcastro, March 1980, p. 141.

Pryde, A., and Gilbert, M.T., *Applications of High Performance Liquid Chromatography*: reviewed by K. Muir, Nov. 1980, p. 120.

Sanders, Paul A., *Handbook of Aerosol Technology*, 2nd ed.; reviewed by J. Ward, Nov. 1980, p. 118.

Sebek, O.K., and Laskin, A.I., eds., *Genetics of Industrial Microorganisms: Proceedings of the Third International Symposium on Genetics of Industrial Microorganisms*; reviewed by V. Bryson, June 1980, p. 105.

Singleton, Paul, and Sainsbury, Diana, *Dictionary of Microbiology*; reviewed by C. Woodward, June 1980, p. 107.

Sittig, Marshall, *Pharmaceutical Manufacturing Encyclopedia*; reviewed by R. Murty, Aug. 1979, p. 72.

Sodano, Charles S., *Vitamin Synthesis, Production, and Use: Advances Since 1970*; reviewed by P. Belcastro, March 1979, p. 89.

Turco, Salvatore, and King, Robert E., *Sterile Dosage Forms: Their Preparation and Clinical Application*, 2nd ed.; reviewed by K. Avis, Oct. 1979, p. 69.

United States Pharmacopeial Convention, Inc., *United States Pharmacopeia Dispensing Information*; reviewed by M. Blake, Sept. 1980, p. 169.

Wardell, William M., ed., *Controlling the Use of Therapeutic Drugs: An International Comparison*; reviewed by J. Swarbrick Jan. 1980, p. 96.

BULKING AGENTS

Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.

Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

CAPPING

Methods of measuring tablet capping. Alex Ritter and Heinz Sucker. Sept. 1980, p. 108.

Studies of variables that affect tablet capping. Alex Ritter and Heinz Sucker. March 1980, p. 56

CAPSULES

Bioavailability of theophylline in soft-gelatin capsules. William R. Ebert. Oct. 1979, p. 60.

Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.

Computerized weight-variation testing for uncoated tablets and capsules. Anthony N. Paruta, Thomas L. Breon, and Douglas S. Greene. March 1980, p. 84.

"Inadequate attention to cleaning," in Washington report. James Dickinson. July 1979, p. 17.
The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. Larry Caldwell, Robyn Cargill, William R. Ebert, and John J. Windheuser. July 1979, p. 52.

CHROMATOGRAPHY

Advances in HPLC: systems and uses. Dale R. Baker and John A. Michnowicz. May 1980, p. 56.
Automation in HPLC analysis. Hamed M. Abdou. May 1980, p. 70.
GMP—method-validation procedures in an OTC firm. Herbert Letterman. Aug. 1980, p. 44.
The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

CLEAN ROOMS

The design of HVAC systems for clean rooms. Martin Kladko. June 1980, p. 90.

COATINGS

Aqueous film coating: an overview. Stuart C. Porter. Sept. 1979, p. 54.
Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.
Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.
The effect of additives on the properties of an aqueous film coating. Stuart C. Porter. March 1980, p. 66.
The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.
Fluid-bed technology applied to pharmaceuticals. Walter Külling and Eduard J. Simon. March 1980, p. 78.
Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.
Sugarcoating the pill: a historical perspective. Glenn Sonnedecker and George Griffenhagen. Sept. 1980, p. 77.

COMPENDIAL MONOGRAPHS EVALUATION AND DEVELOPMENT PROGRAM

The CMED program and compendial independence. John V. Bergen. Aug. 1980, p. 38.
The CMED program: A project leader's view. Robert E. Graham. Aug. 1980, p. 36.
The CMED program and public drug standards. I. David Wolfson. Aug. 1980, p. 29.
The USP-monograph revision process. Martin I. Blake. Aug. 1980, p. 31.

COMPRESSION

The contribution of tableting aids to pharmaceutical development. Earl W. Seugling. July 1980, p. 26.
The development of tablet manufacturing. George B. Griffenhagen. March 1980, p. 45.
Methods of measuring tablet capping. Alex Ritter and Heinz Sucker. March 1980, p. 56.
Studies of variables that affect tablet capping. Alex Ritter and Heinz Sucker. March 1980, p. 56.

COMPUTERS (see AUTOMATION)

CONFLICT OF INTEREST

"Marvin Seife's reinstatement," in Washington report. James Dickinson. Aug. 1980, p. 16.

CONTAMINATION (see also PYROGENS; STERILIZATION)

Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.
Biocontainment process station for parenteral manufacturing. Joachim E. Manning. Nov. 1979, p. 78.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
Microporous-filter sanitization of large-volume product and feed-water systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.
A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.
A new system for generating extremely pure water. Jakob Hoiss. Jan. 1980, p. 62.
Particulate matter in parenteral products. May 1979, p. 30.
Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

CONTROLLED RELEASE

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.

RICHARD CROUT

"Crout bows out," in Washington report. James Dickinson. Sept. 1980, p. 35.
"Crout's policies vindicated," in Washington report. James Dickinson. Dec. 1980, p. 18.
"Marvin Seife's reinstatement," in Washington report. James Dickinson. Aug. 1980, p. 16.
"Richard Crout's resignation," in Regulatory review. Bernard T. Loftus. Nov. 1980, p. 36.

DERMATOLOGY

"Dermatologicals in Europe," in London letter. Peter Bathe. March 1980, p. 22.

DISSOLUTION AND DISINTEGRATION

The automation of dissolution testing. John C. Wahlich. Sept. 1980, p. 92.
Can dissolution testing be a precise method? William A. Hanson. Aug. 1979, p. 8.
The contribution of tableting aids to pharmaceutical development. Earl W. Seugling. July 1980, p. 26.
"Dissolution's worst test," Washington report. James Dickinson. Jan. 1979, p. 19.
"Dissolution testing," in Regulatory review. Bernard T. Loftus. March 1980, p. 29.
Effects of moisture on the dissolution rate of prednisone tablets. William A. Hanson and Royal A. Hanson. March 1979, p. 42.
The influence of media and volume on the dissolution rate of benzbromarone. Helga Möller. Sept. 1980, p. 116.
A new era of tablet disintegrants. Ralph Shangraw, Ampol Mitrevej, and Manoj Shah. Oct. 1980, p. 48.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

DISTILLATION

The generation of pharmaceutical-grade water by distillation. Peter A. DiSessa. Nov. 1980, p. 102.

DNA

Recombinant DNA technology: tool of the 1980s. J. Paul Burnett Jr. and Max M. Marsh. Oct. 1980, p. 42.

DRUG PRODUCT PROBLEM REPORTING SYSTEM

Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.

DRYING

How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.

ECONOMICS

"British pharmaceutical exports," in European report. Peter Bathe. July 1980, p. 17.
FDA thinks small. Minna S. Golden. Sept. 1980, p. 85.
The hidden dividends of drug research. Lewis A. Engman. March 1980, p. 10.
"ITT disposing of European pharmaceutical subsidiaries," in European report. Peter Bathe. April 1980, p. 33.
Patent protection: the declining research incentive. P. Roy Vagelos. Sept. 1980, p. 18.
"Valium pricing battle," in European report. Peter Bathe. April 1980, p. 29.

EDUCATION

Packaging education and research at Michigan State University. C.J. Mackson. Dec. 1980, p. 30.

EFFICACY

"An unrealistic timetable," in Washington report. James Dickinson. May 1979, p. 14.

EMPLOYMENT

Beating the high cost of employment relocation. James A. Crumpley. Nov. 1980, p. 68.
Career advancement in the 1980s. James A. Crumpley. Jan. 1980, p. 40.
Interviews that win jobs. James A. Crumpley. Oct. 1979, p. 42.
Job hunting: a professional approach. James A. Crumpley. June 1979, p. 45.

ENGINEERING

Career advancement in the 1980s. James. A. Crumpley. Jan. 1980, p. 40.
The design of HVAC systems for clean rooms. Martin Kladko. June 1980, p. 90.
Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

EQUIPMENT

The development of tablet manufacturing. George B. Griffenhagen. March 1980, p. 45.
How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.
New pharmaceuticals packaging concepts and machine-system design. C. Bodayla, L. Hansen, and K. Zitzelman. Dec. 1980, p. 34.

ERYTHROMYCIN

"Dr. Sidney M. Wolfe: 'a useful gadfly,' " in Washington report. James Dickinson. Jan. 1980, p. 21.

EXCIPIENTS

Excipients and dosage-form development. Jack Cooper. April 1979, p. 12.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

FACILITIES

Animal-facility design criteria for a toxicologic testing laboratory. Melvin Balk. April 1980, p. 58.
The design of HVAC systems for clean rooms. Martin Kladko. June 1980, p. 90.

FILMS

The effect of additives on the properties of an aqueous film coating. Stuart C. Porter. March 1980, p. 66.
The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.
Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.

FILTRATION

Comments on organism-challenge levels in sterilizing-filter efficiency testing. Peter R. Johnston and Theodore H. Meltzer. Nov. 1979, p. 66.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.
Microporous-filter sanitization of large-volume product and feedwater systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.
Pyrogen control by depth filtration. Charles P. Gerba, Kenneth C. Hou, Richard A. Babineau, and Joseph V. Fiore. June 1980, p. 82.
Suggested integrity testing of membrane filters at a robust flow of air. Peter R. Johnston and Theodore H. Meltzer. Nov. 1980, p. 49.
Theoretical aspects of sterile filtration and integrity testing. H.G. Schroeder and P.P. DeLuca. Nov. 1980, p. 80.
Ultrafiltration in plasma fractionation. Lita L. Nelsen and Adrian R. Reti. May 1979, p. 50.
Upgrading water purity for manufacturing nonsterile pharmaceutical products. Stanley H. Scruton. July 1980, p. 38.
Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.

FLOCCULATION

Intrinsic flowability: a new technology for powder-flowability classification. Alberto Gioia. Feb. 1980, p. 64.

FLUID BED

Fluid-bed technology applied to pharmaceuticals. Walter Külling and Eduard J. Simon. March 1980, p. 78.

FOOD AND DRUG ADMINISTRATION

Consensus grows on drug-law reform. George E. Brown Jr. May 1980, p. 16.
Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.
Drug regulation: a survey of public preferences. John Blydenburgh. Feb. 1980, p. 75.
FDA's Good Laboratory Practice regulations. Paul D. Lepore. June 1979, p. 70.
"FDA and process validation," in Regulatory review. Bernard T. Loftus. Dec. 1980, p. 25.
FDA thinks small. Minna S. Golden. Sept. 1980, p. 85.
GLPs and the Quality Assurance Unit in contract research. Robert D. Fischbeck and Stephen D. Morton. Feb. 1980, p. 70.
How FDA implements its drug quality assurance strategies: field compliance programs. Richard A. Terselic and Charles F. Pyatt. Nov. 1980, p. 86.
LVP sterilization and the proposed CGMPs. Lowell A. Kleiman, Louis Wertman, and Ted Shlisky. June 1980, p. 98.
The need for uniform GLP regulations. Walter C. Gakenheimer. June 1980, p. 52.

On creating a commonwealth of interests. Jere E. Goyan. Jan. 1980, p. 14.
Prescription for an FDA commissioner. Louis Lasagna. Oct. 1979, p. 14.
Regulatory review. Bernard T. Loftus. Monthly column. Jan.–Dec. 1980.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
Washington report. James Dickinson. Monthly column. June 1977–Dec. 1980.

FOOD, DRUG, AND COSMETIC ACT

"CGMP: substantive or interpretive regulations?" in Regulatory review. Bernard T. Loftus. Jan. 1980, p. 29.
"Defeat for Premo," in Washington report. James Dickinson. Oct. 1980, p. 17.
"Four views of the FD&C Act," in Regulatory review. Bernard T. Loftus. May 1980, p. 35.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.

FREEDOM OF INFORMATION ACT

"The Freedom of Information Act," in Washington report. James Dickinson. April 1980, p. 23.

FREE ENTERPRISE

The drug reform act: a reprieve. Ted Rowell Jr. March 1979, p. 8.
Economic incentive: the key to cost-effective medicine. C. Joseph Stetler. July 1979, p. 20.
The future of the pharmaceutical industry in the 1980s. Paul E. Freiman. Jan. 1980, p. 34.

FREEZE DRYING

How to select a pharmaceutical freeze-drying system. Stanley L. Morgan and Marlin R. Spotts. Nov. 1979, p. 94.

FRUCTOSE

Tableting characteristics of pure crystalline fructose. Thomas F. Osberger. June 1979, p. 80.

GENERIC DRUGS

The battle is over, but. . . . William F. Haddad. May 1979, p. 10.
"Defeat for Premo," in Washington report. James Dickinson. Oct. 1980, p. 17.
Economic incentive: the key to cost-effective medicine. C. Joseph Stetler. July 1979, p. 20.
"False disparagement," in Washington report. James Dickinson. Oct. 1979, p. 26.
"FDA answers the Lilly study," in Washington report. James Dickinson. July 1980, p. 15.
"FDA and AUSA," in Regulatory review. Bernard T. Loftus, Sept. 1980, p. 38.
"FDA versus Premo," in Washington report. James Dickinson. June 1980, p. 14.
"Generic prescribing," in European report. Peter Bathe. Aug. 1980, p. 20.
"The L---y study was right," in Washington report. James Dickinson. Nov. 1980, p. 30.
Look-alike drug product litigation and legislation. Nicholas L. Ruggieri. Nov. 1980, p. 38.
"Look-alikes as 'fraud,' " in Washington report. James Dickinson. March 1980, p. 13.
The problems of product selection, patient inserts, and sampling. H.L. Richardson. Oct. 1980, p. 10.
" 'Responsible' generic companies," in Washington report. James Dickinson. Aug. 1980, p. 14.
"Scandal at FDA?" in Washington report. James Dickinson. May 1980, p. 19.
"Son of bioequivalence," in Washington report. James Dickinson. Feb. 1979, p. 17.
"U.K. generic drug controversy," in London letter. Peter Bathe. Feb. 1980, p. 28.

GENETIC ENGINEERING

"The biotechnical revolution," in European report. Peter Bathe. May, 1980, p. 26.
Recombinant DNA technology: tool of the 1980s. J. Paul Burnett Jr. and Max M. Marsh. Oct. 1980, p. 42.

GOOD LABORATORY PRACTICES

The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
FDA's Good Laboratory Practice regulations. Paul D. Lepore. June 1979, p. 70.
GLPs and the Quality Assurance Unit in contract research. Robert D. Fischbeck and Stephen D. Morton. Feb. 1980, p. 70.
"Goaded by abuse disclosures," in Washington report. James Dickinson. March 1979, p. 17.
The impact of GLP regulations on an industrial toxicology laboratory. Hans P. Drobeck. Aug. 1979, p. 34.
The need for uniform GLP regulations. Walter C. Gakenheimer. June 1980, p. 52.

GOOD MANUFACTURING PRACTICES

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
"CGMP: substantive or interpretive regulations?" in Regulatory review. Bernard T. Loftus. Jan. 1980, p. 29.
Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.
"Dissolution testing," in Regulatory review. Bernard T. Loftus. March 1980, p. 29.
Drug stability: compliance. Joel S. Davis. Sept. 1980, p. 102.
"The flexibility of the new CGMPs," in Washington report. James Dickinson. June 1979, p. 12.
GMP–method-validation procedures in an OTC firm. Herbert Letterman. Aug. 1980, p. 44.
"Goaded by abuse disclosures," in Washington report. James Dickinson. March 1979, p. 17.
How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979. p. 52.
"Inadequate attention to cleaning," in Washington report. James Dickinson. July 1979, p. 17.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
"*Limulus* amoebocyte testing," in Regulatory review. Bernard T. Loftus. June 1980, p. 31.
LVP sterilization and the proposed CGMPs. Lowell A. Kleiman, Louis Wertman, and Ted Shlisky. June 1980, p. 98.
A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.
Modern tableting technology and on-line operator training. Frank D. Eaton. Sept. 1980, p. 58.
A new system for generating extremely pure water. Jakob Hoiss. Jan. 1980, p. 62.
"Proposed LVP regulations," in Regulatory review. Bernard T. Loftus. Sept. 1980, p. 44.
The role of pharmaceutical scientists in specifying raw materials. George W. Kurtz. Feb. 1980, p. 14.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
" 'Substantive' GMPs under attack," in Washington report. James Dickinson. April 1980, p. 20.
"Testing raw materials," in Regulatory review. Bernard T. Loftus. Feb. 1980, p. 32.
Training pharmaceutical employees: what's the right way? Dennis B. Gallagher. April 1980, p. 39.
Unit-dose labeling: some considerations. Arthur K. Yellin. Oct. 1980, p. 32.

JERE GOYAN

Jere Goyan: new face at FDA. James Dickinson. Nov. 1979, p. 21.
"A new FDA, Goyan style," in Washington report. James Dickinson. Feb. 1980, p. 18.

GRANULATION

Advantages of continuous tablet granulation. Sept. 1979, p. 49.
Theory of the granulating-liquid requirement in the conventional granulation process. Hans Leuenberger, Hans-Peter Bier, and Heinz B. Sucker. June 1979, p. 60.

HAZARDOUS MATERIALS

Hazardous-chemical safety training. Nancy Kippenhan. Feb. 1979, p. 64.

HEATING, VENTING, AND AIR CONDITIONING

The design of HVAC systems for clean rooms. Martin Kladko. June 1980, p. 90.

HISTORY OF PHARMACY

Dawn of the antibiotic era. John Parascandola. Nov. 1980, p. 60.
The development of the modern pharmaceutical industry. John Parascandola. Oct. 1979, p. 46.
The development of tablet manufacturing. George B. Griffenhagen. March 1980, p. 45.
Hypodermic medication. J.K. Crellin. June 1980, p. 57.
Pharmacy's evolutionary revolution. George A. Bender. Feb. 1980, p. 45.
Sugarcoating the pill: a historical perspective. Glenn Sonnedecker and George Griffenhagen. Sept. 1980, p. 77.

IMPACTORS

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

INFORMATION STORAGE AND RETRIEVAL SYSTEMS

An integrated computer network in pharmaceutical technology. Julian Horwich, Joan Fortune, Harvey J. Hoyt, and Ronald A. Schwartz. Jan. 1980, p. 54.

INK

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

INSTRUMENTATION

Advances in HPLC: systems and uses. Dale R. Baker and John A. Michnowicz. May 1980, p. 56.
Applications of microprocessor-based balances. Bernd Ludewig. May 1980, p. 40.
Automation in HPLC analysis. Hamed M. Abdou. May 1980, p. 70.
Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.
Determining size characteristics of submicrometer particulate systems. M.J. Groves. May 1980, p. 80.
Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.
How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.
Office automation tools for the pharmaceutical laboratory. Caroline Watteeuw. June 1980, p. 42.
Rapid weighing and sorting of filled capsules. Robert L. Demorest. Dec. 1980, p. 40.
The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

INSULIN

"The insulin war, round two," in Washington report. James Dickinson. Nov. 1980, p. 27.
Recombinant DNA technology: tool of the 1980s. J. Paul Burnett Jr. and Max M. Marsh. Oct. 1980, p. 42.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

INTERFERON

"The biotechnical revolution," in European report. Peter Bathe. May 1980, p. 26.
Interferon research: problems and prospects. Lee H. Kronenberg. May 1980, p. 47.

INVESTIGATIONAL NEW DRUG APPLICATIONS (INDs)

"Published studies are not reliable," in Washington report. James Dickinson. Dec. 1979, p. 62.

IRON DEFICIENCY

Iron deficiency: a challenge to the pharmaceutical industry. Leif Hallberg, Selwyn J. Baker, C.O. Chichester, James D. Cook, E.M. DeMaeyer, Harold Newmark, H. Louis Shapiro, and Lester J. Teply. Oct. 1979, p. 34.

LABELING

"CGMP: substantive or interpretive regulations?" in Regulatory review. Bernard T. Loftus. Jan. 1980, p. 29.
Drug stability: compliance. Joel S. Davis. Sept. 1980, p. 102.
Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
Unit-dose labeling: some considerations. Arthur K. Yellin. Oct. 1980, p. 32.

LABORATORY ANIMALS

Animal-facility design criteria for a toxicologic testing laboratory. Melvin Balk. April 1980, p. 58.
Animal rights and animal testing. Andrew N. Rowan. July 1980, p. 10.

LAL (see *LIMULUS* AMOEBOCYTE LYSATE)

LAMINAR FLOW

The design of HVAC systems for clean rooms. Martin Kladko. June 1980, p. 90.
Short-term hot-air sterilization by the laminar-flow process. Wilfried G. Willing. May 1979, p. 68.

***LIMULUS* AMOEBOCYTE LYSATE**

An inquiry into the LAL and rabbit pyrogen tests. Daniel Banes. July 1979, p. 28.
"*Limulus* amoebocyte testing," in Regulatory review. Bernard T. Loftus. June 1980, p. 31.
Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

LOOK-ALIKE DRUGS (see TRADE DRESS)

LUBRICANTS

The contribution of tableting aids to pharmaceutical development. Earl W. Seugling. July 1980, p. 26.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

LYOPHILIZATION (see FREEZE DRYING)

MAN IN THE PLANT

"'Man in the plant' practice," in Washington report. James Dickinson. May 1980, p. 24.

MATERIALS HANDLING

Designing materials-handling containers for the pharmaceutical plant. Dec. 1980, p. 28.

MAXIMUM ALLOWABLE COST (MAC)

"Can you beat a MAC?" in Washington report. James Dickinson. Aug. 1979, p. 13.

The future of the pharmaceutical industry in the 1980s. Paul A. Freiman. Jan. 1980, p. 34.

"Tablets of stone," in Washington report. James Dickinson. Jan. 1979, p. 20.

MEDICAID

"Medicaid won't pay for 'ineffective' drugs," in Washington report. James Dickinson. Feb. 1980, p. 20.

MICROBIOLOGY (see also ANAEROBES; BACTERIOLOGY)

Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.

Biocontainment process station for parenteral manufacturing. Joachim E. Manning. Nov. 1979, p. 78.

Determination of airborne microorganisms in a pharmaceutical plant using standard, elective, and selective culture media. M.A.-F. Abdou. Nov. 1980, p. 92.

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.

The patenting of microorganisms. John L. White. March 1980, p. 37.

Pyrogen control by depth filtration. Charles P. Gerba, Kenneth C. Hou, Richard A. Babineau, and Joseph V. Fiore. June 1980, p. 82.

Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

Theoretical aspects of sterile filtration and integrity testing. H.G. Schroeder and P.P. DeLuca. Nov. 1980, p. 80.

Upgrading water purity for manufacturing nonsterile pharmaceutical products. Stanley H. Scruton. July 1980, p. 38.

Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.

Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

MICROSCOPY

Determining size characteristics of submicrometer particulate systems. M.J. Groves. May 1980, p. 80.

MODELS

A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.

MOISTURE

How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

MULTIVARIATE ANALYSIS (see STATISTICS)

NEW DRUG APPLICATIONS (NDAs) (see also INVESTIGATIONAL NEW DRUG APPLICATIONS)

"Can FDA be fair about Isolone?" in Washington report. James Dickinson. Feb. 1980, p. 22.

"Defeat for Premo," in Washington report. James Dickinson. Oct. 1980, p. 17.

"FDA and AUSA," in Regulatory review. Bernard T. Loftus. Sept. 1980, p. 38.

"FDA promises faster NDAs," in Washington report. James Dickinson. Feb. 1979, p. 22.

"FDA's policy regarding 'paper' NDAs," in Washington report. James Dickinson. Dec. 1979, p. 14.

"FDA versus Premo," in Washington report. James Dickinson. June 1980, p. 14.

"FDA versus Premo — Part II," in Washington report. James Dickinson. Aug. 1980, p. 12.

"FDA won a hollow victory," in Washington report. James Dickinson. Sept. 1980, p. 20.

"Milton Bass talks," in Washington report. James Dickinson. July 1979, p. 16.

" 'Paper' NDAs," in Washington report. James Dickinson. Sept. 1979, p. 26.

"Pharmadyne as phoenix?" in Washington report. James Dickinson. July 1979, p. 17.

Public image, patent status, and "paper" NDAs: an FDA roundtable. Diana Rico. July 1979, p. 32.

"Scandal, scandal, scandal," in Washington report. James Dickinson. Oct. 1980, p. 12.

NIACINAMIDE ASCORBATE

Niacinamide ascorbate: renewed opportunities for tableters. Thomas F. Osberger. Feb. 1980, p. 52.

OINTMENTS

Packaging and the physical stability properties of a nonaqueous topical ointment. R.J. Harwood, J.B. Portnoff, R.E. Dempski, G.P. Polli, C.E. Shoop, and R.A. Castello. Jan. 1980, p. 70.

ORPHAN DRUGS

A home for orphan drugs. Elizabeth Holtzman. Aug. 1980, p. 10.

OXYTOCIN

The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

PACKAGING

"Interphex '80," in European report. Peter Bathe. March 1980, p. 22.

New pharmaceuticals packaging concepts and machine-system design. C. Bodayla, L. Hansen, and K. Zitzelman. Dec. 1980, p. 34.

Packaging and the physical stability properties of a nonaqueous topical ointment. R.J. Harwood, J.B. Portnoff, R.E. Dempski, G.P. Polli, C.E. Shoop, and R.A. Castello. Jan. 1980, p. 70.

Packaging education and research at Michigan State University. C.J. Mackson. Dec. 1980, p. 30.

Unit-dose labeling: some considerations. Arthur K. Yellin. Oct. 1980, p. 32.

"Unit-of-use packaging," in Washington report. James Dickinson. Nov. 1979, p. 34.

"Unit-of-use packaging is on the way," in Washington report. James Dickinson. May 1979, p. 20.

Water-vapor transmission of package systems. Hugh E. Lockhart. Dec. 1980, p. 46.

PARENTERALS

Biocontainment process station for parenteral manufacturing. Joachim E. Manning. Nov. 1979, p. 78.

Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.

Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.

"A far cry from the GLPs," in Washington report. James Dickinson. March 1979, p. 25.

Hypodermic medication. J.K. Crellin. June 1980, p. 57.

"*Limulus* amoebocyte testing," in Regulatory review. Bernard T. Loftus. June, 1980, p. 31.

LVP sterilization and the proposed CGMPs. Lowell A. Kleiman, Louis Wertman, and Ted Shlisky. June 1980, p. 98.
Particulate matter in parenteral products. May 1979, p. 30.
PDA's continuing commitment to research. Jack Cole. Nov. 1980, p. 24.
"Proposed LVP regulations," in Regulatory review. Bernard T. Loftus. Sept. 1980, p. 44.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.
Pyrogen control by depth filtration. Charles P. Gerba, Kenneth C. Hou, Richard A. Babineau, and Joseph V. Fiore. June 1980, p. 82.
Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980. p. 72.

PARTICULATES

Determining size characteristics of submicrometer particulate systems. M.J. Groves. May 1980, p. 80.
Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.
Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.
Microporous-filter sanitization of large-volume product and feed-water systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.
Particulate matter in parenteral products. May 1979, p. 30.

PATENTS

"The importance of patents and copyrights," in London letter. Peter Bathe. Jan. 1980, p. 26.
"Naughty Mead Johnson," in Washington report. James Dickinson. Dec. 1980, p. 18.
Patent protection: the declining research incentive. P. Roy Vagelos. Sept. 1980, p. 18.
The patenting of microorganisms. John L. White. March 1980, p. 37.

PATIENT PACKAGE INSERTS

"APhA rejects mandatory PPIs," in Washington report. James Dickinson. Dec. 1980, p. 18.
"FDA hits USP on PPIs," in Washington report. James Dickinson. April 1980, p. 27.
" 'Generic' patient package inserts," in Washington report. James Dickinson. March 1979, p. 20.
Inaccurate and misleading package inserts. Peter Barna. Nov. 1980, p. 74.
On creating a commonwealth of interests. Jere E. Goyan. Jan. 1980, p. 14.
"Patient package inserts," in Washington report. James Dickinson. Jan. 1980, p. 25.
The problems of product selection, patient inserts, and sampling. H.L. Richardson. Oct. 1980, p. 10.
A year for drug-law reform. Donald Kennedy. Jan. 1979, p. 16.

PENICILLIN

Dawn of the antibiotic era. John Parascandola. Nov. 1980, p. 60.

PERSONNEL

Modern tableting technology and on-line operator training. Frank D. Eaton. Sept. 1980, p. 58.
Training pharmaceutical employees: what's the right way? Dennis B. Gallagher. April 1980, p. 39.

PHARMACEUTICAL TECHNOLOGY

The contribution of tableting aids to pharmaceutical development. Earl W. Seugling. July 1980, p. 26.
Fluid-bed technology applied to pharmaceuticals. Walter Külling and Eduard J. Simon. March 1980, p. 78.
The generation of pharmaceutical-grade water by distillation. Peter A. DiSessa. Nov. 1980, p. 102.
Hypodermic medication. J.K. Crellin. June 1980, p. 57.
The influence of media and volume on the dissolution rate of benzbromarone. Helga Möller. Sept. 1980, p. 116.
Intrinsic flowability: a new technology for powder-flowability classification. Alberto Gioia. Feb. 1980, p. 64.
Phase-transfer catalysis in the production of pharmaceuticals. Lars Lindblom and Magnus Elander. Oct. 1980, p. 58.
Upgrading water purity for manufacturing nonsterile pharmaceutical products. Stanley H. Scruton. July 1980, p. 38.

PHARMACY (see also HISTORY OF PHARMACY)

Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.

PHASE-TRANSFER CATALYSIS

Phase-transfer catalysis in the production of pharmaceuticals. Lars Lindblom and Magnus Elander. Oct. 1980, p. 58.

PIGMENTS (see also INKS)

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.
The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.
The effect of additives on the properties of an aqueous film coating. Stuart C. Porter. March 1980, p. 66.

PLASMA

Ultrafiltration in plasma fractionation. Lita L. Nelsen and Adrian R. Reti. May 1979, p. 50.

PLASTICIZERS

The effect of additives on the properties of an aqueous film coating. Stuart C. Porter. March 1980, p. 66.

POWDERS

Intrinsic flowability: a new technology for powder-flowability classification. Alberto Gioia. Feb. 1980, p. 64.

PRECIPITATORS

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

PREDNISONE

"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
Effects of moisture on the dissolution rate of prednisone tablets. William A. Hanson and Royal A. Hanson. March 1979, p. 42.
" 'Generic' patient package inserts," in Washington report. James Dickinson. March 1979, p. 20.

PRODUCTIVITY

Office automation tools for the pharmaceutical laboratory. Caroline Watteeuw. June 1980, p. 42.

PROPANOLOL

"Propanolol: generic versus brand-name products," in European report. Peter Bathe. Aug. 1980, p. 22.
"UK generic-drug controversy," in London letter. Peter Bathe. Feb. 1980, p. 30.

PROPOXYPHENE

"Ah, sweet elixir of propoxyphene!" in Washington report. James Dickinson. April 1979, p. 16.
"Whatever FDA does is wrong," in Washington report. James Dickinson. Nov. 1979, p. 32.

PSEUDOMONAS

Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

PYROGENS (see also CONTAMINATION; STERILIZATION)

Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.

An inquiry into the LAL and rabbit pyrogen tests. Daniel Banes. July 1979, p. 28.

"*Limulus* amoebocyte testing," in Regulatory review. Bernard T. Loftus. June 1980, p. 31.

A new system for generating extremely pure water. Jakob Hoiss. Jan. 1980, p. 62.

Pyrogen control by depth filtration. Charles P. Gerba, Kenneth C. Hou, Richard A. Babineau, and Joseph V. Fiore. June 1980, p. 82.

Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

QUALITY ASSURANCE AND CONTROL

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.

Career advancement in the 1980s. James A. Crumpley. Jan. 1980, p. 40.

Comments on organism-challenge levels in sterilizing-filter efficiency testing. Peter R. Johnston and Theodore H. Meltzer. Nov. 1979, p. 66.

Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.

Computerized weight-variation testing for uncoated tablets and capsules. Anthony N. Paruta, Thomas L. Breon, and Douglas S. Greene. March 1980, p. 84.

Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.

Determination of airborne microorganisms in a pharmaceutical plant using standard, elective, and selective culture media. M. A.-F. Abdou. Nov. 1980, p. 92.

"Dissolution testing," in Regulatory review. Bernard T. Loftus. March 1980, p. 29.

Drug quality: who has the answer? Robert J. Creevy. Feb. 1979, p. 10.

Drug stability: compliance. Joel S. Davis. Sept. 1980, p. 102.

The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.

Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.

Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.

GLPs and the Quality Assurance Unit in contract research. Robert D. Fischbeck and Stephen D. Morton. Feb. 1980, p. 70.

GMP—method-validation procedures in an OTC firm. Herbert Letterman. Aug. 1980, p. 44.

How FDA implements its drug quality assurance strategies: field compliance programs. Richard A. Terselic and Charles F. Pyatt. Nov. 1980, p. 86.

How to select a pharmaceutical freeze-drying system. Stanley L. Morgan and Marlin R. Spotts. Nov. 1979, p. 94.

A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.

Pharmacy's evolutionary revolution. George A. Bender. Feb. 1980, p. 45.

Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

Pyrogen control by depth filtration. Charles P. Gerba, Kenneth C. Hou, Richard A. Babineau, and Joseph V. Fiore. June 1980, p. 82.

Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

Suggested integrity testing of membrane filters at a robust flow of air. Peter R. Johnston and Theodore H. Meltzer. Nov. 1980, p. 49.

The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.

Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.

Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

RADIATION

Radiometric detection of *Pseudomonas aeruginosa* in pharmaceutical products. Amiya Chatterjee. April 1980, p. 44.

RADIOPHARMACEUTICALS

A fortress for radiopharmaceuticals. Aug. 1979, p. 32.

RAW MATERIALS

Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.

A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.

Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.

The role of pharmaceutical scientists in specifying raw materials. George W. Kurtz. Feb. 1980, p. 14.

"Testing raw materials," in Regulatory review. Bernard T. Loftus. Feb. 1980, p. 32.

REGULATIONS

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.

As I see it. Edward S. Brady. Feb. 1979, p. 41.

"CGMP: substantive or interpretive regulations?" in Regulatory review. Bernard T. Loftus. Jan. 1980, p. 29.

The challenge of self-regulation. C. Joseph Stetler. June 1979, p. 8.

The CMED program and compendial independence. John V. Bergen. Aug. 1980, p. 38.

The CMED program: a project leader's view. Robert E. Graham. Aug. 1980, p. 36.

The CMED program and public drug standards. I. David Wolfson. Aug. 1980, p. 29.

Consensus grows on drug-law reform. George E. Brown Jr. May 1980, p. 16.

"Current proposals," in London letter. Peter Bathe. Oct. 1979, p. 29.

"DEA decontrols 141 drugs," in Washington report. James Dickinson. Jan. 1978, p. 61.

"Dissolution testing," in Regulatory review. Bernard T. Loftus. March 1980, p. 29.

"Documenting the USP," in Regulatory review. Bernard T. Loftus. Oct. 1980, p. 20.

"Dr. Sidney M. Wolfe, 'a useful gadfly,'" in Washington report. James Dickinson. Jan. 1980, p. 21.

Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.

The drug reform act: a reprieve. Ted Rowell Jr. March 1979, p. 8.

Drug regulation: a survey of public preferences. John Blydenburgh. Feb. 1980, p. 75.

Drug stability: compliance. Joel S. Davis. Sept. 1980, p. 102.

The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.

FDA's Good Laboratory Practice regulations. Paul D. Lepore. June 1979, p. 70.
FDA thinks small. Minna S. Golden. Sept. 1980, p. 85.
"FDA versus Premo," in Washington report. James Dickinson. June 1980, p. 14.
"FDA versus Premo — Part II," in Washington report. James Dickinson. Aug. 1980, p. 12.
"Four views of the FD&C Act," in Regulatory review. Bernard T. Loftus. May 1980, p. 34.
The future of the pharmaceutical industry in the 1980s. Paul E. Freiman. Jan. 1980, p. 34.
GLPs and the Quality Assurance Unit in contract research. Robert. D. Fischbeck and Stephen D. Morton. Feb. 1980, p. 70.
GMP—method-validation procedures in an OTC firm. Herbert Letterman. Aug. 1980, p. 44.
"Government regulation in Britain," in London letter. Peter Bathe. Jan. 1980, p. 26.
The impact of GLP regulations on an industrial toxicology laboratory. Hans P. Drobeck. Aug. 1979, p. 34.
In behalf of balance and optimism. Irwin Lerner. April 1980, p. 12.
"Last chance for drug-law reform?" in Washington report. James Dickinson. May 1979, p. 18.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
"Look-alike drug products," in Washington report. James Dickinson. Oct. 1979, p. 24.
LVP sterilization and the proposed CGMPs. Lowell A. Kleiman, Louis Wertman, and Ted Shlisky. June 1980, p. 98.
"Milton Bass talks," in Washington report. James Dickinson. July 1979, p. 16.
The need for uniform GLP regulations. Walter C. Gakenheimer. June 1980, p. 52.
"New IFPMA compendium," in European report. Peter Bathe. July 1980, p. 18.
"Preclinical testing streamlined," in European report. Peter Bathe. June 1980, p. 24.
"Primodos controversy," in European report. Peter Bathe. Aug. 1980, p. 20.
"Proposed LVP regulations," in Regulatory review. Bernard T. Loftus. Sept. 1980, p. 44.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
"Senator Kennedy holds the key," in Washington report. James Dickinson. Nov. 1979, p. 40.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
"'Substantive' GMPs under attack," in Washington report. James Dickinson. April 1980, p. 20.
Therapeutic equivalence in a restructured drug market. James Dickinson. April 1979, p. 72.
Unit-dose labeling: some considerations. Arthur K. Yellin. Oct. 1980, p. 32.
The USP-monograph revision process. Martin I. Blake. Aug. 1980, p. 31.
Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.
A year for drug-law reform. Donald Kennedy. Jan. 1979, p. 16.

RESEARCH AND DEVELOPMENT

Animal rights and animal testing. Andrew N. Rowan. July 1980, p. 10.
Career advancement in the 1980s. James A. Crumpley. Jan. 1980, p. 40.
A commitment to excellence and awareness. Patrick P. DeLuca. July 1979, p. 10.
Consensus grows on drug-law reform. George E. Brown Jr. May 1980, p. 16.
The double guarantee. Robert F. Dee. June 1980, p. 12.
The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
The future of the pharmaceutical industry in the 1980s. Paul E. Freiman. Jan. 1980, p. 34.
GLPs and the Quality Assurance Unit in contract research. Robert D. Fischbeck and Stephen D. Morton. Feb. 1980, p. 70.
The hidden dividends of drug research. Lewis A. Engman. March 1980, p. 10.
A home for orphan drugs. Elizabeth Holtzman. Aug. 1980, p. 10.
Interferon research: problems and prospects. Lee H. Kronenberg. May 1980, p. 47.
Patent protection: the declining research incentive. P. Roy Vagelos. Sept. 1980, p. 18.
PDA's continuing commitment to research. Jack Cole. Nov. 1980, p. 24.
Prospects for the 1980s. John J. Horan. Sept. 1979, p. 24.
"Upjohn has the best erythromycin," in Washington report. James Dickinson. June 1979, p. 18.

RESINS

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.
Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

SAFETY

Hazardous-chemical safety training. Nancy Kippenhan. Feb. 1979, p. 64.

SAMPLING

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.
Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.
Determination of airborne microorganisms in a pharmaceutical plant using standard, elective, and selective culture media. M.A.-F. Abdou. Nov. 1980, p. 92.
Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.
Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.
The problems of product selection, patient inserts, and sampling. H.L. Richardson. Oct. 1980, p. 10.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

SOLVENTS

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

SORBENTS

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

SPECTROSCOPY

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.
The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

STABILITY

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
A computerized drug-stability system. Harold A. Stone and James G. Slater. April 1980, p. 52.
Drug stability: compliance. Joel S. Davis. Sept. 1980, p. 102.
Packaging and the physical stability properties of a nonaqueous topical ointment. R.J. Harwood, J.B. Portnoff, R.E. Dempski, G.P. Polli, C.E. Shoop, and R.A. Castello. Jan. 1980, p. 70.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.

STANDARDS

Antibiotic batch certification: a regulatory device that has outlived

its usefulness. George H. Schneller. Nov. 1979, p. 47.
The CMED program and compendial independence. John V. Bergen. Aug. 1980, p. 38.
The CMED program: a project leader's view. Robert E. Graham. Aug. 1980, p. 36.
The CMED program and public drug standards. I. David Wolfson. Aug. 1980, p. 29.
"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
LVP sterilization and the proposed CGMPs. Lowell A. Kleiman, Louis Wertman, and Ted Shlisky. June 1980, p. 98.
Pharmacy's evolutionary revolution. George A. Bender, Feb. 1980, p. 45.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.
The USP-monograph revision process. Martin I. Blake. Aug. 1980, p. 31.

STATISTICS

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.
Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.
Multivariate statistical analysis in pharmaceutical research. Allan R. Sampson. Jan. 1979, p. 36.
Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.

STERILIZATION (see also CONTAMINATION; PYROGENS)

Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
LVP sterilization and the proposed CGMPs. Lowell A. Kleiman, Louis Wertman, and Ted Shlisky. June 1980, p. 98.
A new system for generating extremely pure water. Jakob Hoiss. Jan. 1980, p. 62.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.
Short-term hot-air sterilization by the laminar-flow process. Wilfried G. Willing. May 1979, p. 68.
Sterilizer validation. Paul L. Simmons. April 1979, p. 68.
Theoretical aspects of sterile filtration and integrity testing. H.G. Schroeder and P.P. DeLuca. Nov. 1980, p. 80.

TABLETS AND TABLETING

Advantages of continuous tablet granulation. Sept. 1979, p. 49.
Aqueous film coating: an overview. Stuart C. Porter. Sept. 1979, p. 54.
Computerization of coupled quality control parameters for uncoated tablets. Douglas S. Greene and Anthony N. Paruta. Sept. 1980, p. 126.
Computerized weight-variation testing for uncoated tablets and capsules. Anthony N. Paruta, Thomas L. Breon, and Douglas S. Greene. March 1980, p. 84.
The contribution of tableting aids to pharmaceutical development. Earl W. Seugling. July 1980, p. 26.
The development of tablet manufacturing. George B. Griffenhagen. March 1980, p. 45.
The effect of additives on the properties of an aqueous film coating. Stuart C. Porter. March 1980, p. 66.
Methods of measuring tablet capping. Alex Ritter and Heinz Sucker. Sept. 1980, p. 108.
Modern tableting technology and on-line operator training. Frank D. Eaton. Sept. 1980, p. 58.
A new era of tablet disintegrants. Ralph Shangraw, Ampol Mitrevej, and Manoj Shah. Oct. 1980, p. 48.
Niacinamide ascorbate: renewed opportunites for tableters. Thomas F. Osberger. Feb. 1980, p. 52.
Rapid weighing and sorting of filled capsules. Robert L. Demorest. Dec. 1980, p. 40.
Studies of variables that affect tablet capping. Alex Ritter and Heinz Sucker. March 1980, p. 56.
Tableting characteristics of pure crystalline fructose. Thomas F. Osberger. June 1979, p. 80.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.
The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. Larry Caldwell, Robyn Cargill, William R. Ebert, and John J. Windheuser. July 1979, p. 52.

TEMPERATURE

Packaging and the physical stability properties of a nonaqueous topical ointment. R.J. Harwood, J.B. Portnoff, R.E. Dempski, G.P. Polli, C.E. Shoop, and R.A. Castello. Jan. 1980, p. 70.

TESTING

Animal-facility design criteria for a toxicologic testing laboratory. Melvin Balk. April 1980, p. 58.
Animal rights and animal testing. Andrew N. Rowan. July 1980, p. 10.
Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.
Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.
Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.
Can dissolution testing be a precise method? William A. Hanson. Aug. 1979, p. 8.
Comments on organism-challenge levels in sterilizing-filter efficiency testing. Peter R. Johnston and Theodore H. Meltzer. Nov. 1979, p. 66.
A computerized drug-stability system. Harold A. Stone and James G. Slater. April 1980, p. 52.
Controlling the quality of bulk pharmaceutical chemicals. Robert W. Hanson. Oct. 1980, p. 26.
Determination of airborne microorganisms in the pharmaceutical plant using standard, elective, and selective culture media. M.A.-F. Abdou. Nov. 1980, p. 92.
"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
"Dissolution testing," in Regulatory review. Bernard T. Loftus. March 1980, p. 29.
"Drug carcinogenicity," in Washington report. James Dickinson. Aug. 1979, p. 16.
Drug stability: compliance. Joel S. Davis. Sept. 1980, p. 102.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Intrinsic flowability: a new technology for powder-flowability classification. Alberto Gioia. Feb. 1980, p. 64.
"*Limulus* amoebocyte testing," in Regulatory review. Bernard T. Loftus. June 1980, p. 31.
A model system for testing raw materials for microbial content. Jan R. Bonalsky. Feb. 1980, p. 48.
"Preclinical testing procedures," in European report. Peter Bathe. March 1980, p. 24.
"Preclinical testing streamlined," in European report. Peter Bathe. June 1980, p. 24.
Predicting the time course of in vivo bioavailability from in vitro dis-

Circle Reader Service Card No. 34 →

solution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.
Purity standards for ingredients used in parenteral preparations. Ram Murty and John Kapoor. Feb. 1980, p. 60.
Pyrogen control by depth filtration. Charles P. Gerba, Kenneth C. Hou, Richard A. Babineau, and Joseph V. Fiore. June 1980, p. 82.
"Rat tests as cancer barometers," in Washington report. James Dickinson. July 1979, p. 18.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
Suggested integrity testing of membrane filters at a robust flow of air. Peter R. Johnston and Theodore H. Meltzer. Nov. 1980, p. 49.
"Testing raw materials," in Regulatory review. Bernard T. Loftus. Feb. 1980, p. 32.
Theoretical aspects of sterile filtration and integrity testing. H.G. Schroeder and P.P. DeLuca. Nov. 1980, p. 80.
Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

THEOPHYLLINE

Bioavailability of theophylline in soft-gelatin capsules. William R. Ebert. Oct. 1979, p. 60.

TOXICOLOGY

Animal-facility design criteria for a toxicologic testing laboratory. Melvin Balk. April 1980, p. 58.
Animal rights and animal testing. Andrew N. Rowan. July 1980, p. 10.

TRADE DRESS

Look-alike drug product litigation and legislation. Nicholas L. Ruggieri. Nov. 1980, p. 38.
"Look-alikes as 'fraud,' " in Washington report. James Dickinson. March 1980, p. 13.
"Propanolol: generic versus brand-name products," in European report. Peter Bathe. Aug. 1980, p. 22.
"UK generic-drug controversy," in London letter. Peter Bathe. Feb. 1980, p. 28.

TRADE SECRETS

"The Freedom of Information Act," in Washington report. James Dickinson. April 1980, p. 23.

TRAINING

Hazardous-chemical safety training. Nancy Kippenhan. Feb. 1979, p. 64.
Modern tableting technology and on-line operator training. Frank D. Eaton. Sept. 1980, p. 58.
"Training for regulatory affairs," in Washington report. James Dickinson. Sept. 1980, p. 36.
Training pharmaceutical employees: what's the right way? Dennis B. Gallagher. April 1980, p. 39.

ULCERS

The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. Larry Caldwell, Robyn Cargill, William R. Ebert, and John J. Windheuser. July 1979, p. 52.

UNITED STATES PHARMACOPEIA

The CMED program and compendial independence. John V. Bergen. Aug. 1980, p. 38.
The CMED program: a project leader's view. Robert E. Graham. Aug. 1980, p. 36.
The CMED program and public drug standards. I. David Wolfson. Aug. 1980, p. 29.
"Dissolution testing," in Regulatory review. Bernard T. Loftus. March 1980, p. 29.
"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
"Documenting the USP," in Regulatory review. Bernard T. Loftus. Oct. 1980, p. 20.
"FDA hits USP on PPIs," in Washington report. James Dickinson. April 1980, p. 27.
"*Limulus* amoebocyte testing," in Regulatory review. Bernard T. Loftus. June 1980, p. 31.
On creating a compendial organization. William M. Heller. Nov. 1979, p. 12.
"A single drug-name system," in Washington report. James Dickinson. March 1979, p. 87.
USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.
The USP-monograph revision process. Martin I. Blake. Aug. 1980, p. 31.
"USP's bottom line," in Washington report. James Dickinson. July 1980, p. 12.
"USP's forum," in Regulatory review. Bernard T. Loftus. Sept. 1980, p. 47.
"USP's future," in Washington report. James Dickinson. Jan. 1979, p. 19.
"USP's growing importance," in Washington report. James Dickinson. Dec. 1980, p. 18.
Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

UNIVARIATE STATISTICAL ANALYSIS (see STATISTICS)

VACCINES

"Vaccination controversy," in European report. Peter Bathe. July 1980, p. 18.

VALIDATION

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
"CGMPs: substantive or interpretive regulations?" in Regulatory review. Bernard T. Loftus. Jan. 1980, p. 29.
"FDA and process validation," in Regulatory review. Bernard T. Loftus. Dec. 1980, p. 25.
GMP—method-validation procedures in an OTC firm. Herbert Letterman. Aug. 1980, p. 44.
Process validation for solid dosage forms. Robert A. Nash. June 1979, p. 104.
Sterilizer validation. Paul L. Simmons. April 1979, p. 68.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.
Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.
Validation of the LAL test for end-product evaluation. James F. Cooper and Michael E. Neely. June 1980, p. 72.

WATER

The generation of pharmaceutical-grade water by distillation. Peter A. DiSessa. Nov. 1980, p. 102.
A new system for generating extremely pure water. Jakob Hoiss. Jan. 1980, p. 26.
Upgrading water purity for manufacturing nonsterile pharmaceutical products. Stanley H. Scruton. July 1980, p. 38.

WATER FOR INJECTION

Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.
Microporous-filter sanitization of large-volume product and feedwater systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.

WORD PROCESSING

An integrated computer network in pharmaceutical technology. Julian Horwich, Joan Fortune, Harvey J. Hoyt, and Ronald A. Schwartz. Jan. 1980, p. 54.
Office automation tools for the pharmaceutical laboratory. Caroline Watteeuw. June 1980, p. 42.

Circle Reader Service Card No. 35